[go: up one dir, main page]

Testa et al., 2019 - Google Patents

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants

Testa et al., 2019

View HTML @Full View
Document ID
7589874699784929303
Author
Testa S
Legnani C
Antonucci E
Paoletti O
Dellanoce C
Cosmi B
Pengo V
Poli D
Morandini R
Testa R
Tripodi A
Palareti G
of START2-Register C
Publication year
Publication venue
Journal of Thrombosis and Haemostasis

External Links

Snippet

Essentials• Currently, DOACs are given at fixed doses and do not require laboratory monitoring.• Direct oral anticoagulant‐specific measurements were performed at trough and peak.• Patients who developed bleeding events showed higher DOAC plasma levels at …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Testa et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
Testa et al. Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants
Gankam Kengne et al. Mild hyponatremia and risk of fracture in the ambulatory elderly
Kreutz et al. Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study
Acevedo et al. Fibrinogen: associations with cardiovascular events in an outpatient clinic
Levy et al. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers
Chen et al. Association of Parenteral Anticoagulation Therapy with Outcomes in Chinese patients undergoing percutaneous coronary intervention for non–ST-segment elevation acute coronary syndrome
Douketis et al. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure
Ofek et al. International normalized ratio is significantly elevated with rivaroxaban and apixaban drug therapies: a retrospective study
Candeloro et al. Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort
Mehta et al. Traditional and emerging sex-specific risk factors for cardiovascular disease in women
Sridharan et al. The Mayo Clinic experience with psychogenic purpura (Gardner-Diamond syndrome)
Tahaineh et al. Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
Ono et al. Risk of post-extraction bleeding with direct oral anticoagulant compared with warfarin: retrospective cohort study using large scale claims data in Japan
Le Mao et al. Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study
Bavalia et al. Direct oral anticoagulant blood level monitoring in daily practice
Nissan et al. Apixaban levels in octogenarian patients with non-valvular atrial fibrillation
Mosquera et al. Prediction of pulmonary embolism in patients with SARS-CoV-2 infection
Summers et al. A multicenter retrospective study evaluating the impact of desmopressin on hematoma expansion in patients with antiplatelet-associated intracranial hemorrhage
Andrade et al. Applicability of the 12-Item Short-Form Health Survey in patients with progressive systemic sclerosis
Schoergenhofer et al. Defibrotide enhances fibrinolysis in human endotoxemia–a randomized, double blind, crossover trial in healthy volunteers
Shimomura et al. Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation
Nelson et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial
Bakow et al. Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation
Yayan et al. No independent influence of statins on the chronic obstructive pulmonary disease exacerbation rate: a cohort observation study over 10 years